Vera Therapeutics Statistics
Total Valuation
VERA has a market cap or net worth of $3.05 billion. The enterprise value is $2.53 billion.
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VERA has 71.78 million shares outstanding. The number of shares has increased by 13.13% in one year.
| Current Share Class | 71.78M |
| Shares Outstanding | 71.78M |
| Shares Change (YoY) | +13.13% |
| Shares Change (QoQ) | +8.92% |
| Owned by Insiders (%) | 0.86% |
| Owned by Institutions (%) | 82.48% |
| Float | 52.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 40.12 |
| PB Ratio | 6.10 |
| P/TBV Ratio | 6.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.64, with a Debt / Equity ratio of 0.15.
| Current Ratio | 13.64 |
| Quick Ratio | 13.30 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -50.70 |
Financial Efficiency
Return on equity (ROE) is -71.32% and return on invested capital (ROIC) is -41.10%.
| Return on Equity (ROE) | -71.32% |
| Return on Assets (ROA) | -38.90% |
| Return on Invested Capital (ROIC) | -41.10% |
| Return on Capital Employed (ROCE) | -66.50% |
| Weighted Average Cost of Capital (WACC) | 9.42% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.09M |
| Employee Count | 339 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, VERA has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +82.15% in the last 52 weeks. The beta is 0.95, so VERA's price volatility has been similar to the market average.
| Beta (5Y) | 0.95 |
| 52-Week Price Change | +82.15% |
| 50-Day Moving Average | 36.09 |
| 200-Day Moving Average | 37.57 |
| Relative Strength Index (RSI) | 72.82 |
| Average Volume (20 Days) | 1,532,537 |
Short Selling Information
The latest short interest is 10.83 million, so 15.09% of the outstanding shares have been sold short.
| Short Interest | 10.83M |
| Short Previous Month | 10.08M |
| Short % of Shares Out | 15.09% |
| Short % of Float | 20.81% |
| Short Ratio (days to cover) | 10.86 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -383.41M |
| Pretax Income | -368.95M |
| Net Income | -368.95M |
| EBITDA | -382.89M |
| EBIT | -383.41M |
| Earnings Per Share (EPS) | -$5.57 |
Full Income StatementBalance Sheet
The company has $596.76 million in cash and $76.89 million in debt, giving a net cash position of $519.87 million or $7.24 per share.
| Cash & Cash Equivalents | 596.76M |
| Total Debt | 76.89M |
| Net Cash | 519.87M |
| Net Cash Per Share | $7.24 |
| Equity (Book Value) | 499.70M |
| Book Value Per Share | 6.97 |
| Working Capital | 570.65M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$293.20 million and capital expenditures -$466,000, giving a free cash flow of -$293.66 million.
| Operating Cash Flow | -293.20M |
| Capital Expenditures | -466,000 |
| Depreciation & Amortization | 523,000 |
| Net Borrowing | 23.34M |
| Free Cash Flow | -293.66M |
| FCF Per Share | -$4.09 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |